Sani nudge has developed a hand hygiene tool that prompts medical professionals to clean their hands more often. Courtesy of TMC

Sani nudge, a graduate of the TMCx healthcare accelerator's nineth cohort at Houston's Texas Medical Center, is getting a significant nudge from a new collaboration with a social-impact organization based in California.

Among more than 1,000 startups that were considered, Copenhagen, Denmark-based Sani nudge was chosen as one of nine participants in the Mistletoe Research Fellowship Startup Collaboration Program, sponsored by the Mistletoe Foundation. Three dozen researchers from seven universities also are taking part in the program.

Fresh off a $1.2 million funding round, Sani nudge's technology is an automated monitoring system aimed at helping healthcare workers bolster hygiene compliance and processes through insights from data and a feature that "nudges" healthcare workers to practice proper hand hygiene. Sani nudge created the technology in conjunction with Bispebjerg Hospital and Aarhus University Hospital, both in Denmark.

In the Mistletoe program, representatives of Sani nudge will work alongside four American researchers to improve the startup's technology, thereby providing hospitals with better data and tapping the researchers' expertise in engineering and robotics to come up with related healthcare platforms. Sani nudge employs 13 people in the U.S., Denmark, and Poland.

During tests in healthcare settings, the use of Sani nudge has resulted in a jump in hand hygiene compliance of as much as 200 percent and a reduction in infections of at least 29 percent, the company says. Several hospitals in Scandinavia are using the Sani nudge system.

Theis Jensen, CEO of Sani nudge, and Dr. Marco Bo Hansen, the chief customer officer, became acquainted with Mistletoe when they met Mark Castleman — a partner at the Mistletoe Inc. global-impact investment fund — during a startup and innovation tour of Texas organized by Capital Factory, a startup accelerator with locations in Houston, Austin, and Dallas.

The three men soon found common ground in a shared vision for reducing hospital-acquired infections and combating resistance to antibiotics. Both are costly, potentially fatal problems.

At any given time, 1 in 25 patients in the U.S. are fighting hospital-acquired infections, the U.S. Department of Health and Human Services says. "These infections lead to the loss of tens of thousands of lives," according to the department, "and cost the U.S. healthcare system billions of dollars each year."

Meanwhile, more than 2 million people in the U.S. are infected each year with antibiotic-resistant bacteria, and at least 23,000 people die as a result, according to the U.S. Centers for Disease Control and Prevention (CDC).

Sani nudge's participation in the Mistletoe program kicked off July 31 and August 1 at a workshop in Tokyo. For the next nine months, the Sani nudge group — led by Rebekah Alexander, the startup's in-house data expert — will team up with its four assigned researchers to advance the startup's wireless technology.

The researchers "will work with us over the following academic year to help us take the Sani nudge solution to the next level and enable hospitals to get even more detailed hand hygiene information that can eliminate hospital-acquired infections," Sani nudge wrote on its blog.

In June 2020, the next-level Sani nudge technology is scheduled to be presented to potential investors and academic researchers in Silicon Valley. Sani nudge says Mistletoe effort will strengthen its ties to the U.S. market and the academic research community.

"There are many opportunities within healthcare IoT that can help both patients and hospitals, and our system is designed to embrace these opportunities," Hansen says.

Hansen, a physician, says he'll be vigilantly advocating that his Sani nudge colleagues and the Mistletoe researchers keep hospital patients and staff in mind as Sani nudge moves forward with its innovations.

"We have to make sure that our solutions always generate value to the end users and can easily be used by the clinicians, infection preventionists, and hospital managers," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.